Phase 1 Pharmacokinetic Study of Tapentadol Prolonged-Release 250 Milligram (mg) Formulation in Healthy Participants
Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate pharmacokinetics (explores what the body does to the
drug), safety and tolerability of single and multiple-dose of tapentadol in healthy
participants.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.